IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo (Q39568860)

13 September 2017

title

IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo (English)

1 reference

13 September 2017

Martine Lamfers

6

0 references

Maikel P Peppelenbosch

object named as

Maikel Peppelenbosch

15

0 references

author name string

Linda B C Bralten

1

1 reference

13 September 2017

Nanne K Kloosterhof

2

1 reference

13 September 2017

Rutger Balvers

3

1 reference

13 September 2017

Andrea Sacchetti

4

1 reference

13 September 2017

Lariesa Lapre

5

1 reference

13 September 2017

Sieger Leenstra

7

1 reference

13 September 2017

Hugo de Jonge

8

1 reference

13 September 2017

Johan M Kros

9

1 reference

13 September 2017

Erwin E W Jansen

10

1 reference

13 September 2017

Eduard A Struys

11

1 reference

13 September 2017

Cornelis Jakobs

12

1 reference

13 September 2017

Gajja S Salomons

13

1 reference

13 September 2017

Sander H Diks

14

1 reference

13 September 2017

Andreas Kremer

16

1 reference

13 September 2017

Casper C Hoogenraad

17

1 reference

13 September 2017

Peter A E Sillevis Smitt

18

1 reference

13 September 2017

Pim J French

19

1 reference

13 September 2017

publication date

1 March 2011

1 reference

13 September 2017

1 reference

13 September 2017

volume

69

1 reference

13 September 2017

issue

3

1 reference

13 September 2017

page(s)

455-463

1 reference

Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?

13 September 2017

cites work

1 reference

Mutant metabolic enzymes are at the origin of gliomas

21 January 2018

1 reference

Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.

21 January 2018

1 reference

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

21 January 2018

1 reference

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma

21 January 2018

1 reference

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas

21 January 2018

1 reference

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

21 January 2018

1 reference

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network

21 January 2018

1 reference

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

Analysis of the IDH1 codon 132 mutation in brain tumors

21 January 2018

1 reference

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

Analysis of IDH1 and IDH2 mutations in Japanese glioma patients

21 January 2018

1 reference

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

Mutagenesis and Laue structures of enzyme intermediates: isocitrate dehydrogenase

21 January 2018

1 reference

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

21 January 2018

1 reference

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

21 January 2018

1 reference

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

21 January 2018

1 reference

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

The CASPR2 cell adhesion molecule functions as a tumor suppressor gene in glioma.

21 January 2018

1 reference

Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma.

21 January 2018

1 reference

Measurement of urinary D- and L-2-hydroxyglutarate enantiomers by stable-isotope-dilution liquid chromatography-tandem mass spectrometry after derivatization with diacetyl-L-tartaric anhydride

21 January 2018

1 reference

Exploration, normalization, and summaries of high density oligonucleotide array probe level data

21 January 2018

1 reference

Kinome profiling using peptide arrays in eukaryotic cells

21 January 2018

1 reference

Kinome profiling in pediatric brain tumors as a new approach for target discovery

21 January 2018

1 reference

Expression of integrin alpha6beta1 enhances tumorigenesis in glioma cells

21 January 2018

1 reference

Gallic acid suppresses cell viability, proliferation, invasion and angiogenesis in human glioma cells

21 January 2018

1 reference

IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors

21 January 2018

1 reference

U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line

21 January 2018

1 reference

IDH mutations in glioma and acute myeloid leukemia

21 January 2018

1 reference

IDH2 mutations in patients with D-2-hydroxyglutaric aciduria

21 January 2018

1 reference

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication

21 January 2018

1 reference

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ANA.22390

1 reference

13 September 2017

1 reference